The ubiquitin ligase MDM2 reduces c‐Cbl‐mediated STAT5 degradation by competitive binding to STAT5 with c‐Cbl, thereby enhancing tumor‐infiltrating CD8+ T cell‐mediated antitumor immunotherapy (tumor size reduction).197. This evidence concerns the gene CD8A and neoplasm.